GANX - CIK 0001819411
The table below shows Gain Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.73M | -$3.82M | -$3.59M | -$4.22M | -$2.45M | -$2.81M |
| Capital expenditure | - | - | - | - | $7.83K | $28.49K |
| Investing cash flow | - | - | $3.02M | $2.11M | -$7.83K | -$28.49K |
| Dividends paid | - | - | - | - | - |
Gain Therapeutics, Inc. reported operating cash flow of -$18.47M for fiscal year 2025. That is up 2.2% from -$18.87M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$3.24M (FY 2020) to -$18.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $404.32K | $2.40M | -$145.80K | $748.91K | -$37.97K | $41.99M |